Article Figures & Data
Figures
- Figure 1.
Effect of Crizotinib in Patients With ALK and ROS1 Gene Fusions
PFS=progression-free survival; FISH+=fluorescence in situ hybridization-positive.
Reproduced from Camidge DR et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncology 2012;13(10);1011–1019. With permission from Elsevier.
- Figure 2.
Better Than Expected Response to Second-Generation ALK and ROS1 Inhibitors
RECIST=response evaluation criteria in solid tumors; DCR=disease control rate; ORR=overall response rate; CNG=copy number gain.
Reproduced with permission from RC Doebele, MD, PhD.
Tools
Table of contents
Cited By...
- No citing articles found.